Immunotherapy of kidney cancer. Where do the T lymphocytes go in kidney cancer?

我们的研究目的：-在一组肾细胞癌中，通过免疫组化检测（CD4+ AP/ CD8+ DAB）， CD103 DAB， CD39 DAB的表达-图像采集将使用蔡司扫描仪完成，上皮，肿瘤和间质区域将使用QuPath 0.2.0-m8软件在每个样本上进行注释。肿瘤区域排除坏死、血细胞、血管区域。-内部的阳性免疫细胞将通过颜色反卷积和阈值调整来检测。-通过光密度和测量阳性细胞检测，并创建测量图。-检测次数，阳性和阴性，阳性细胞百分比和每mm_2阳性细胞数将被记录下来供我们分析。-将对某些样本中的群集图进行评估，以确定是否存在与肿瘤相关的特定模式的阳性免疫细胞。-分析CD103和CD39细胞在肿瘤和良性上皮之间的定位，将临床和病理数据与我们的结果相关联。

Aims of our study: - Expression of (CD4+ AP/ CD8+ DAB), CD103 DAB, CD39 DAB will be determine by IHC in a group of renal cell carcinomas - Images acquisition will be done using a Zeiss scanner and epithelial, tumor and stroma areas will be annotated on each sample using the QuPath 0.2.0-m8 software. Areas of necrosis, blood cells, blood vessels were excluded from the tumor areas. - Positive immune cells within will be detected by color deconvolution and threshold adjustments. - Positive cell detection was measure by optical density sum, and measurements maps created. - Number of detections, positive ad negative, percentage of positive cells and number pf positive cells per mm_2 will be recorded for our analysis. - Cluster maps will be evaluated in some samples to determine the presence or not of a specific pattern of positive immune cell in relation with tumor ones. - The CD103 and CD39 cells location will be analyzed between tumor and benign epithelium and clinical and pathological data will be correlated with our results.